ArticleFrontiers in cell and developmental biology2026
Cell line authentication: a commercial service provider perspective.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell line misidentification and cross contamination continue to undermine research quality despite improved laboratory practices. Short Tandem Repeat (STR) profiling remains the primary method for human cell line authentication and is increasingly required by journals, funders, and regulatory bodies. Analysis of authentication data generated at NorthGene™ in 2024-2025 demonstrates that misidentification and contamination remain prevalent, with 4.7% of lines misidentified and 1.8% contaminated in 2024, and 2.4% misidentified with 1.6% contaminated in 2025. Primary cell lines present additional challenges, as none submitted during this period met ASN 0002 standards for full traceability, posing risks to reproducibility and downstream biological interpretation. Mixture analysis proved essential for resolving inconclusive STR results and identifying specific contaminants, although progress is hindered when reference STR profiles are not publicly available. While STR profiling is highly discriminatory for human cells, complementary methods-such as species specific PCR and CO1 barcoding-may be required to detect interspecies contamination or authenticate non human lines. Overall, these findings highlight the ongoing need for rigorous authentication workflows and complete traceability to ensure scientific integrity and prevent invalid research outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.